ORCHIECTOMY VERSUS ZOLADEX PLUS EULEXIN IN PATENTS WITH METASTATIC PROSTATE-CANCER (EORTC-30853)

被引：14

作者：

DENIS, L

ROBINSON, M

MAHLER, C

SMITH, P

KEUPPENS, F

DEMOURA, JLC

BONO, A

NEWLING, D

SYLVESTER, R

DEPAUW, M

VERMEYLEN, K

ONGENA, P

机构：

[1] ST JAMES UNIV HOSP, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND

[2] FREE UNIV AMSTERDAM, ACAD ZIEKENHUIS, 1007 MC AMSTERDAM, NETHERLANDS

[3] HOSP SANTA MARIA, LISBON, PORTUGAL

[4] OSPED CIRCOLO VARESE, VARESE, ITALY

[5] FDN ES MACCHI, VARESE, ITALY

[6] EUROPEAN ORG RES TREATMENT CANC, CTR DATA, BRUSSELS, BELGIUM

[7] VRIJE UNIV BRUSSELS, ACAD ZIENKENHUIS, B-1050 BRUSSELS, BELGIUM

[8] PONTEFRACT GEN HOSP, PONTEFRACT, W YORKSHIRE, ENGLAND

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 1990年 / 37卷 / 06期

关键词：

D O I：

10.1016/0960-0760(90)90449-U

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A total of 327 patients with metastic prostate cancer have been randomized to either orchidectomy or treatment with goserelin (Zoladez(R)) 3.6 mg depot preparation combined with flutamide (Eulexin(R)) 250 mg t.i.d. in a phase III study (EORTC 30853). A small but statistically significant difference in time to subjective and objective progression of disease was found in favour of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchidectomy. Thus no difference was found in overall survival between the two treatment groups. The clinical significance of these differences requires further follow up and analysis.

引用

页码：951 / 959

页数：9

共 5 条

[1] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].